QCG
RYTM icon

Quadrant Capital Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Quadrant Capital Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42
Closed -$4.24K – 2773
2025
Q3 		$4.24K Buy
+42
New +$3.9K ﹤0.01% 2348
2022
Q2 		– Sell
-154
Closed -$2K – 2704
2022
Q1 		$2K Buy
+154
New +$1.35K ﹤0.01% 2186
2021
Q2 		– Sell
-6
Closed – – 2533
2021
Q1 		$0 Hold
6
– – ﹤0.01% 2448
2020
Q4 		$0 Hold
6
– – ﹤0.01% 2366
2020
Q3 		$0 Buy
+6
New +$138 ﹤0.01% 2289

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quadrant Capital Group's RYTM Position: Q4 2025 in Review

Quadrant Capital Group sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 42 shares — an estimated $4.24K sold.

Quadrant Capital Group first reported a position in RYTM in Q3 2020 and held it in 5 quarters. The position peaked at $4.24K in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Quadrant Capital Group reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 42 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $4.24K.
  • Quadrant Capital Group first reported a position in Rhythm Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Quadrant Capital Group's Rhythm Pharmaceuticals position peaked at $4.24K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Quadrant Capital Group's 13F filing for Q4 2025, filed 13 Feb 2026.